Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Targeting distinct therapeutic vulnerabilities in homologous repair-deficient pancreatic adenocarcinoma
EF 2018-19
Résumé
Pancreatic cancer (PAC) will become the second-leading cause of cancer death in North America by 2030. The 5-year survival is a dismal 8%, and responses to chemotherapy are poor. Pancreatic cancer continues to be treated as a single disease, with patients generally receiving one-size-fits-all chemotherapy regimens. Recent advances have shown that there are, in fact, many distinct subtypes of pancreatic cancer. An important subtype is homologous repair-deficient PAC (HRD-PAC), which arises from genetic mutations that impair the tumour's ability to repair genetic errors. This subtype may be sensitive to targeted therapies that specifically exploit the tumour's unique vulnerabilities.
A major challenge in developing targeted therapies for HRD-PAC is the lack of robust animal models and patient tissue samples. To address this need, we have built a research program nested within a high-volume pancreatic cancer centre, allowing fluid access to patient samples. To generate patient-derived mouse models of HRD-PAC, pancreatic tumours are collected directly from the operating room, and transplanted into immune-deficient mice. Using these mouse models, I am conducting a preclinical trial to evaluate the efficacy of various targeted therapies. I will also use these mouse models to study how tumours develop resistance to targeted therapies, and strategies to overcome this resistance. Finally, I will use human tissue samples to study the interaction between the tumour and the immune system, to identify potential immune therapies which may be effective in HRD-PAC. Altogether, this work will better our understanding of targeted treatment strategies for HRD-PAC, and have important, real-time clinical implications for patients suffering from this deadly disease.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
396350
Name
Wang Yifan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Targeting distinct therapeutic vulnerabilities in homologous repair-deficient pancreatic adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Homologous Repair Deficiency; Pancreatic Cancer; Patient-Derived Xenograft; Personalized Medicine; Platinum; Poly (Adp-Ribose) Polymerase Inhibitor; Precision Oncology; Resistance Mechanisms; Targeted Therapy; Tumour Immune Microenvironment
Abstract
Pancreatic cancer (PAC) will become the second-leading cause of cancer death in North America by 2030. The 5-year survival is a dismal 8%, and responses to chemotherapy are poor. Pancreatic cancer continues to be treated as a single disease, with patients generally receiving one-size-fits-all chemotherapy regimens. Recent advances have shown that there are, in fact, many distinct subtypes of pancreatic cancer. An important subtype is homologous repair-deficient PAC (HRD-PAC), which arises from genetic mutations that impair the tumour's ability to repair genetic errors. This subtype may be sensitive to targeted therapies that specifically exploit the tumour's unique vulnerabilities.
A major challenge in developing targeted therapies for HRD-PAC is the lack of robust animal models and patient tissue samples. To address this need, we have built a research program nested within a high-volume pancreatic cancer centre, allowing fluid access to patient samples. To generate patient-derived mouse models of HRD-PAC, pancreatic tumours are collected directly from the operating room, and transplanted into immune-deficient mice. Using these mouse models, I am conducting a preclinical trial to evaluate the efficacy of various targeted therapies. I will also use these mouse models to study how tumours develop resistance to targeted therapies, and strategies to overcome this resistance. Finally, I will use human tissue samples to study the interaction between the tumour and the immune system, to identify potential immune therapies which may be effective in HRD-PAC. Altogether, this work will better our understanding of targeted treatment strategies for HRD-PAC, and have important, real-time clinical implications for patients suffering from this deadly disease.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wang, Yifan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~